OptimizeRx Co. (NASDAQ:OPRX) CEO William J. Febbo Acquires 20,000 Shares

OptimizeRx Co. (NASDAQ:OPRX) CEO William J. Febbo acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the purchase, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

OptimizeRx Stock Performance

OPRX stock traded up $0.33 on Monday, hitting $5.32. The company had a trading volume of 406,916 shares, compared to its average volume of 160,485. The stock has a market cap of $97.99 million, a price-to-earnings ratio of -3.98 and a beta of 1.34. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock’s 50-day simple moving average is $5.55 and its 200 day simple moving average is $8.01. OptimizeRx Co. has a 12-month low of $3.78 and a 12-month high of $16.65.

Institutional Trading of OptimizeRx

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in shares of OptimizeRx by 9.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company’s stock valued at $1,117,000 after purchasing an additional 10,041 shares during the last quarter. Summit Securities Group LLC purchased a new stake in OptimizeRx during the second quarter valued at approximately $25,000. Legato Capital Management LLC raised its position in OptimizeRx by 74.0% in the second quarter. Legato Capital Management LLC now owns 59,693 shares of the company’s stock worth $597,000 after acquiring an additional 25,377 shares during the period. Rhumbline Advisers boosted its stake in shares of OptimizeRx by 9.2% during the 2nd quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock worth $315,000 after acquiring an additional 2,658 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its stake in shares of OptimizeRx by 23.5% during the 2nd quarter. Rice Hall James & Associates LLC now owns 496,135 shares of the company’s stock worth $4,961,000 after acquiring an additional 94,253 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on OPRX shares. JMP Securities cut their price target on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 14th. Royal Bank of Canada reduced their price target on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Roth Mkm reiterated a “buy” rating and issued a $16.00 price target (down previously from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. Barclays reduced their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, November 14th. Finally, Stifel Nicolaus dropped their target price on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, OptimizeRx has an average rating of “Moderate Buy” and an average price target of $10.42.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.